NCT05215847View on ClinicalTrials.gov

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions

Bariatric SurgeryObesityWeight Gain

Interventions

DRUG

ARD-101

Twice daily, oral administration

Trial Locations (1)

92037

Altman Clinical and Translational Research Institute, University of California, San Diego, San Diego

Sponsors

Lead Sponsor

Aardvark Therapeutics, Inc.

All Listed Sponsors

collaborator

University of California, San Diego

OTHER

lead

Aardvark Therapeutics, Inc.

INDUSTRY